A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for F508del and a Minimal Function Mutation (F/MF) (NCT05033080)
VX20-121-102
This study is no longer recruiting patients. The following details are for information only.
This trial is Recently completed/closed
Registration number NCT05033080
Program & service
This trial is being run with the Heart & Lung service, and as part of the Respiratory program.
Trial phase
Phase 3
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Associate Professor Tom Kotsimbos
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTRIf you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.